VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
North Valley Breast Clinic 1335 Buenaventura Blvd #204, CA USA
geo.som@outlook.com (412) 770-6906
